The End of Process Validation As We Know It? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
The End of Process Validation As We Know It?
Much has changed in the 18 years since FDA issued its process validation guidelines. Is it time to move on?


Pharmaceutical Technology


In 1987, when the US Food and Drug Administration issued its Guideline on General Principles of Process Validation, a young FDA reviewer asked her supervisors, "What does this term validation really mean?"

"We don't know," they responded.

Much has changed in the past 18 years. So much has changed, in fact, that the current concept of process validation, once a fresh idea in quality control, and which later became accepted dogma, may now be ready for the trash bin. With companies achieving new levels of process understanding, what does it mean to validate a manufacturing process? Industry leaders and FDA are now examining that question and looking at new models to follow.

Losing sight of the goal

Although the 1987 guideline did not introduce the concept of validation, it did plant the notion firmly in industry. It defined validation as:

establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality attributes (1).


The continuous quality verification model
That seems logical enough. The problem, many experts say, is that over time validation activities have become centered on documentation instead of on ensuring quality. "It's a forest for the trees situation," says Russell E. Madsen, president of The Williamsburg Group (Gaithersburg, MD, http://www.thewilliamsburggroup.com/). "A whole industry grew up around process validation. It has resulted in a proliferation of validation protocols, validation reports, and validation documentation; but you still have processes out there that don't work." We've lost sight of the goal, Madsen says, "which is to demonstrate the process reliably does what it's supposed to do. It's as simple as that."

Validating without understanding

Fernando Muzzio, PhD, a professor in the Department of Biochemical Engineering at Rutgers University (Piscataway, NJ, http://www.rutgers.edu/) says the main problem underlying the traditional approach to validation is that that we don't understand our manufacturing processes very well. And if we don't, our validation activities are essentially meaningless. "How can we agree to validate a process we don't understand?" he asks. "You know the old tale about the emperor's new clothes? Well, that's validation. Validation is, and always was, a fantasy."


ADVERTISEMENT

RELATED CONTENT
Is Real-Time Release Through PAT Compatible with the Ideal of "Science-Based Regulation?"
Integrating PAT into Processes
Mathematical Modeling Speeds Process Scale-Up and Transfer at P&G
FDA's CMC Pilot Program Moves Forward
Contract Manufacturers Gear Up For PAT
post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here